טוען...
Immunomodulatory Therapy for Melanoma: Ipilimumab and Beyond
In 2011, the FDA approved the first new therapy for melanoma in over a decade, ipilimumab (Yervoy). Ipilimumab is a novel antibody that blockscytotoxic T lymphocyte-associated antigen 4 (CTLA-4), a regulatory molecule expressed on activated T cells. Blockade of this important immune checkpoint can l...
שמור ב:
| Main Authors: | , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2013
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3653249/ https://ncbi.nlm.nih.gov/pubmed/23438382 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clindermatol.2012.08.006 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|